Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000214008 | SCV000272820 | uncertain significance | not specified | 2015-10-30 | criteria provided, single submitter | clinical testing | The p.Gly30953Asp variant in TTN has not been previously reported in individuals with cardiomyopathy, but has been identified in 1/65532 European chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP r s370516977). Computational prediction tools and conservation analysis suggest th at the p.Gly30953Asp variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical signi ficance of the p.Gly30953Asp variant is uncertain. |
Ambry Genetics | RCV002381749 | SCV002674936 | uncertain significance | Cardiovascular phenotype | 2019-05-30 | criteria provided, single submitter | clinical testing | The p.G24456D variant (also known as c.73367G>A), located in coding exon 184 of the TTN gene, results from a G to A substitution at nucleotide position 73367. The glycine at codon 24456 is replaced by aspartic acid, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |